Claudia Angela Maria Fulgenzi

机构：Hammersmith Hospital, Imperial College London · ORCID：0000-0002-5654-9225

发表论文 205 篇 · 总被引 2525 次 · h-index 29

代表论文

• Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction (2025 · Gut · 被引 16)
• Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study (2025 · JHEP Reports · 被引 12)
• Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma (2025 · JAMA Oncology · 被引 9)
• Hepatocellular carcinoma in people living with HIV (2025 · Journal of Hepatology · 被引 9)
• Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence (2025 · JHEP Reports · 被引 9)
• ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab (2025 · Journal of Hepatocellular Carcinoma · 被引 5)